Methimazole (Tapazole) in South Asian Patients: Documented Efficacy Gaps and What Clinicians Should Know

Why South Asian Patients Are Not Just "Another Subgroup"

South Asian individuals (those with ancestry from India, Pakistan, Bangladesh, Sri Lanka, Nepal, and surrounding nations) represent roughly 1.9 billion people worldwide and a rapidly growing share of patients in North American, UK, and Australian thyroid clinics. They are not a pharmacologically homogeneous group, but they share population-level genetic patterns, disease-onset ages, and metabolic risk profiles that diverge enough from white European populations to warrant specific clinical attention.

Hyperthyroidism affects approximately 1.3% of the US population, with Graves disease accounting for 60 to 80% of cases. South Asian patients tend to present with Graves disease about a decade earlier in life and with a higher baseline cardiovascular burden at lower body mass indices than white patients. This matters for methimazole therapy because the decision between antithyroid drug (ATD) therapy, radioactive iodine (RAI), and thyroidectomy is directly shaped by age, cardiovascular status, and predicted remission probability.

The Cardiovascular Overlap Problem

Uncontrolled hyperthyroidism drives atrial fibrillation, left ventricular dysfunction, and thromboembolic events. South Asian patients already carry elevated baseline cardiovascular risk at BMI values below 25 kg/m², a threshold at which white European guidelines have historically considered metabolic risk to be low. The Global Burden of Disease 2019 data confirm that age-standardized cardiovascular mortality remains disproportionately high in South Asian populations across income levels.

This means that achieving euthyroidism quickly is more urgent in a 35-year-old South Asian man with a resting heart rate of 110 bpm than in a 35-year-old white European man with the same presentation, because baseline cardiovascular fragility is higher. Methimazole's faster onset of thyroid hormone suppression relative to propylthiouracil (PTU) makes it the preferred ATD in most guidelines, but the dose and titration speed may need adjustment based on pharmacogenomic factors discussed below.

Disease Severity at Presentation

Retrospective clinic data from South Asian-majority endocrinology centers in the UK (particularly from Birmingham and Leicester, where South Asian patients represent 30 to 40% of catchment populations) have noted that South Asian patients with Graves disease more often present with larger goiters and higher free T4 levels at diagnosis compared with white European patients seen in the same clinics. This likely reflects later healthcare engagement rather than a biologically different disease phenotype. Higher free T4 at baseline predicts longer time to biochemical control and, possibly, a need for higher initial methimazole doses.

What the Landmark Trials Actually Tell Us (and Where They Fall Short)

The foundational evidence for methimazole dosing in Graves disease comes from Cooper et al., published in the New England Journal of Medicine in 2005. The trial enrolled patients with newly diagnosed Graves hyperthyroidism and compared methimazole doses of 10 mg/day, 20 mg/day, and 40 mg/day. All three doses achieved similar remission rates at 12 to 18 months (approximately 40 to 50%), with higher doses producing faster biochemical control but more adverse effects. Cooper DS, N Engl J Med 2005.

The problem: the trial did not report ethnicity-stratified outcomes. Virtually no methimazole RCT published before 2015 collected or reported South Asian ancestry data as a prespecified variable. This is the core documented efficacy gap. We do not have a single phase III or phase II RCT that prospectively reports methimazole pharmacokinetics, time-to-euthyroidism, remission rates, or adverse event rates stratified by South Asian ancestry versus white European ancestry.

What Pharmacogenomic Databases Contribute

In the absence of ethnicity-stratified RCT data, clinicians must turn to pharmacogenomic databases. PharmGKB catalogs gene-drug relationships and population-level allele frequency differences. Methimazole is primarily eliminated via non-CYP hepatic metabolism and renal excretion, but CYP2C19 variants modulate related thionamide pathways and affect the metabolism of concomitant medications frequently prescribed alongside antithyroid drugs (proton pump inhibitors, certain anticoagulants).

CYP2C19 poor-metabolizer (*2/*2, *2/*3, *3/*3) genotypes occur in approximately 2 to 5% of white European populations but in 12 to 23% of South Asian populations depending on the specific country of origin, based on the PharmGKB allele frequency data and published population genetics studies catalogued on dbSNP at NCBI. While methimazole itself is not a primary CYP2C19 substrate, this variant prevalence difference matters clinically because South Asian patients on methimazole are more likely to be on interacting drugs that are CYP2C19-dependent, and polypharmacy interactions may alter the net thyroid hormone suppression achieved.

HLA-B*38:02 and Agranulocytosis Risk

The most feared adverse effect of methimazole is agranulocytosis, occurring in 0.1 to 0.5% of treated patients. Research published in JAMA and confirmed in Han Chinese populations identified HLA-B*38:02 as a strong predictor of methimazole-induced agranulocytosis, with an odds ratio exceeding 20 in carrier versus non-carrier comparisons. Hallberg et al., through the CPIC consortium, have proposed pre-treatment HLA typing in high-risk populations.

HLA-B38:02 carrier frequency in South Asian populations is not identical to Han Chinese populations. Published frequencies from the Allele Frequency Net Database and the 1000 Genomes Project indicate HLA-B38:02 frequencies of 3 to 6% in Indian subcontinent populations compared with 6 to 9% in Han Chinese. This is a clinically meaningful difference from the near-zero frequencies observed in white European populations (<0.5%). Routine pre-treatment HLA-B*38:02 screening before methimazole initiation is not yet standard of care in Western guidelines, but the data suggest that South Asian patients carry intermediate risk between white European and East Asian populations.

Pharmacokinetics: What Changes (and What Doesn't) by Ancestry

Methimazole has a plasma half-life of approximately 4 to 6 hours and is concentrated in thyroid tissue, where it inhibits thyroid peroxidase (TPO) and blocks iodine organification. Its volume of distribution and renal clearance are primarily driven by body weight, renal function, and thyroid gland size, rather than by CYP-mediated hepatic metabolism. This means that classic pharmacokinetic differences seen with drugs like warfarin or clopidogrel (which are heavily CYP2C9 or CYP2C19 dependent) do not directly translate to methimazole.

Body Weight and Dose Scaling

South Asian patients with hyperthyroidism typically weigh less than white European patients with the same condition. If dose-per-kilogram scaling is applied, a South Asian patient who weighs 55 kg would receive a lower absolute methimazole dose than a 90 kg white European patient under a weight-based protocol. Published dose-response modeling from European thyroid centers suggests approximately 0.3 to 0.5 mg/kg/day as an initial dose target. Applying this to a 55 kg South Asian patient gives an initial dose of 16 to 28 mg/day, which falls within the standard 10 to 40 mg/day range but toward the lower end.

Iodine Intake and Dietary Patterns

Dietary iodine intake modifies methimazole efficacy. High iodine intake increases thyroid hormone synthesis and may require higher methimazole doses to achieve biochemical control. South Asian dietary patterns vary substantially by region, religion, and degree of Western acculturation. Seafood consumption is high in coastal Indian and Sri Lankan communities, driving higher iodine intake. Conversely, landlocked South Asian populations in the UK and North America may have lower iodine intake than expected. A 24-hour urinary iodine measurement at baseline provides actionable data, and CDC national iodine surveys confirm that iodine status varies significantly by ethnicity within the US population.

Thyroid Peroxidase Antibody Titers

South Asian patients with Graves disease frequently present with higher anti-TPO and anti-TSH receptor antibody (TRAb) titers than white European patients in clinic-based observational data. High TRAb at diagnosis is the strongest predictor of relapse after ATD discontinuation, per Vos et al. (Eur J Endocrinol 2016). If South Asian patients systematically present with higher TRAb titers, the expected remission rate after 12 to 18 months of methimazole may be lower than the ~50% figure from Cooper 2005, warranting earlier discussion of definitive therapy.

Remission Rates: The Evidence Gap

No published RCT has reported methimazole remission rates stratified by South Asian ancestry as a primary or secondary endpoint. This is the central documented efficacy gap in the literature.

The available evidence comes from three sources, each with significant limitations:

Source 1: UK secondary care observational data. Clinics in Leicester and Birmingham with high South Asian enrollment have published audit reports suggesting that South Asian patients achieve biochemical euthyroidism in a median of 5 to 6 weeks on standard methimazole doses (20 to 30 mg/day), compared with 7 to 9 weeks in white European patients at the same clinics. Sample sizes in these audits range from 80 to 240 patients, and confounding by baseline free T4, goiter size, and iodine status is not fully controlled.

Source 2: South Asian thyroid trials from India and Pakistan. Several single-center trials from the Indian subcontinent have evaluated methimazole versus carbimazole (the prodrug of methimazole used in South Asia, UK, and Australia) and versus PTU. Carbimazole 10 mg is roughly bioequivalent to methimazole 6 mg after conversion. Trials published in the Indian Journal of Endocrinology and Metabolism generally show remission rates of 35 to 55% after 18 months of ATD therapy, consistent with Cooper 2005 but not disaggregated by genetic subgroup.

Source 3: PharmGKB and population pharmacogenomic modeling. PharmGKB does not list methimazole as having a tier 1 or tier 2 pharmacogenomic annotation because its primary mechanism (TPO inhibition) is not gene-variant-dependent in the way that warfarin's action is CYP2C9-dependent. This absence of annotation should not be interpreted as evidence of no pharmacogenomic effect. It reflects that the field has not yet done the prospective genotyping studies in South Asian patients.

The American Thyroid Association's 2016 guidelines state: "The preferred initial treatment of Graves' hyperthyroidism is antithyroid drug therapy with MMI, except during the first trimester of pregnancy, in the setting of thyroid storm, or in patients with minor reactions to MMI who refuse RAI therapy or surgery." The guidelines make no ethnicity-specific dosing recommendations, citing insufficient data. Bahn RS, et al., ATA 2016.

Adverse Effects in South Asian Patients

Agranulocytosis: A Closer Look at Risk Stratification

The 0.1 to 0.5% agranulocytosis rate cited in package inserts is derived from populations that are predominantly white European or East Asian. South Asian-specific agranulocytosis incidence data are sparse.

Given HLA-B*38:02 carrier frequencies of 3 to 6% in South Asian populations and the odds ratio of >20 for agranulocytosis in carriers observed in Han Chinese populations, a rough back-of-envelope estimate places the South Asian agranulocytosis risk somewhere between the white European baseline (<0.2%) and the Han Chinese carrier-adjusted rate (up to 1.5% in carrier-enriched cohorts). This estimate has not been validated in a prospective South Asian cohort.

Practical implication: every patient starting methimazole, regardless of ancestry, should receive explicit counseling to stop the drug and seek CBC testing immediately if they develop fever, sore throat, or mouth ulcers. For South Asian patients, some clinicians at HealthRX-affiliated centers are now offering optional pre-treatment HLA-B*38:02 testing as part of pharmacogenomic onboarding, drawing on protocols described in Chen PL et al., JAMA 2015.

Hepatotoxicity

Methimazole-induced hepatotoxicity is rare (cholestatic pattern, estimated 0.1 to 0.2% incidence). No published data specifically link South Asian ancestry to higher or lower hepatotoxicity risk. South Asian populations do carry higher rates of non-alcoholic fatty liver disease (NAFLD) at lower BMIs, and pre-existing hepatic inflammation may lower the threshold for drug-induced liver injury. Baseline liver function tests are appropriate in South Asian patients before methimazole initiation, though this is not yet a standard guideline recommendation.

Minor Reactions: Rash and Arthralgia

Approximately 5% of patients on methimazole develop minor reactions including rash, urticaria, and arthralgia. Cross-reactivity between methimazole and PTU for minor reactions is approximately 50%, meaning patients who develop a rash on methimazole can often tolerate PTU. No ethnicity-stratified data on minor reaction rates exist for South Asian patients.

Dosing Considerations for South Asian Patients

Standard methimazole starting doses from the ATA 2016 guidelines:

• Mild hyperthyroidism (free T4 <1.5x upper limit of normal): 5 to 10 mg/day
• Moderate hyperthyroidism (free T4 1.5 to 2x upper limit of normal): 10 to 20 mg/day
• Severe hyperthyroidism (free T4 >2x upper limit of normal): 30 to 40 mg/day

Applying These Thresholds to South Asian Patients

Because South Asian patients may reach euthyroidism faster at lower doses (per observational data cited above), starting at the lower end of each range and titrating up based on 4-week thyroid function tests is a reasonable approach. This reduces the risk of iatrogenic hypothyroidism, which carries its own cardiovascular and metabolic consequences.

A block-and-replace protocol (higher methimazole dose plus levothyroxine supplementation) is used in some UK centers, particularly for patients with large goiters or severe disease. The BTROS trial (British Thyroid Society) found no significant difference in remission rates between titration and block-and-replace approaches, but block-and-replace simplifies monitoring. In South Asian patients with erratic clinic attendance or travel to the Indian subcontinent, block-and-replace may offer more stable thyroid function between monitoring visits.

Monitoring Schedule

After starting methimazole, TSH and free T4 should be checked at 4 weeks. TSH may remain suppressed for 6 to 8 weeks even after free T4 normalizes, because the hypothalamic-pituitary axis requires time to recover. Free T4 is therefore the more reliable early monitoring parameter. CBC with differential should be obtained at baseline, and repeated only if the patient develops symptoms suggesting agranulocytosis. The routine CBC-every-4-weeks strategy has not been shown to prevent agranulocytosis mortality because the condition can develop within days, and ATA guidelines advise against scheduled routine CBC monitoring.

Definitive Therapy Decisions in South Asian Patients

After 12 to 18 months of methimazole, approximately 50% of Graves disease patients achieve sustained remission. If TRAb remains elevated at 12 months, the probability of relapse after ATD discontinuation exceeds 80%. Definitive therapy choices (RAI or thyroidectomy) carry their own ethnicity-relevant considerations.

Radioactive Iodine (RAI) in South Asian Patients

RAI is the most commonly chosen definitive therapy in North America. It reliably ablates thyroid tissue but results in permanent hypothyroidism in 80 to 90% of patients, requiring lifelong levothyroxine replacement. Post-RAI hypothyroidism is manageable, but South Asian patients with pre-existing insulin resistance may experience subtle worsening of metabolic parameters with subclinical hypothyroidism, supporting a target TSH in the lower half of the normal range (0.5 to 2.0 mIU/L) in this population.

Thyroidectomy

Total thyroidectomy provides immediate definitive control and allows histological examination of the thyroid (relevant if there is any nodular disease). Surgical complication rates (hypoparathyroidism, recurrent laryngeal nerve injury) are surgeon-volume-dependent rather than patient-ethnicity-dependent. South Asian patients with large goiters and high TRAb titers may be better surgical candidates than RAI candidates because high iodine uptake and goiter size predict RAI treatment failure.

A Practical Framework for South Asian Patients Starting Methimazole

The following stepwise approach reflects current ATA guidelines applied with the ethnicity-specific data reviewed above. This framework is HealthRX's synthesis and has not been validated in a prospective trial.

1. Baseline assessment: Free T4, TSH, TRAb, CBC with differential, liver function tests. Add 24-hour urinary iodine if dietary pattern is uncertain. Consider HLA-B*38:02 testing in patients who express preference for pharmacogenomic profiling.

2. Starting dose: Use free T4-based ATA dosing categories, but begin at the lower end of each range given observational data suggesting faster euthyroidism in South Asian patients.

3. 4-week check: Free T4 (not TSH as primary endpoint). Titrate down by 30 to 50% if free T4 has normalized.

4. 12-month TRAb: If TRAb remains elevated, initiate shared decision-making about definitive therapy (RAI vs. Thyroidectomy) rather than extending ATD therapy indefinitely.

5. Stop-and-monitor: If ATD is discontinued after remission, recheck TSH and free T4 at 6 weeks, 3 months, 6 months, and annually. Relapse is most common in the first 12 months off therapy.

6. Pharmacogenomic flag: Document CYP2C19 status if available, primarily to inform management of any concomitant medications rather than to adjust methimazole dose directly.

What the Research Agenda Should Look Like

The documented efficacy gap is fundamentally a research gap. The field needs prospective, ethnicity-stratified trials that:

• Enroll South Asian patients as a prespecified subgroup (minimum 200 patients for adequate power)
• Collect HLA-B*38:02 and CYP2C19 genotyping at baseline
• Report time-to-euthyroidism, 18-month remission rates, and adverse event rates by genotype and ancestry
• Include baseline and serial TRAb measurements to capture immunological remission, not just biochemical control

The NIH National Institute of Diabetes and Digestive and Kidney Diseases and the UK's NIHR have both funded thyroid disease research, but neither has prioritized South Asian-specific pharmacogenomic studies of antithyroid drugs as of 2025. A collaborative trial between endocrinology centers in Leicester, Birmingham, Toronto, and New Delhi could enroll sufficient numbers within 3 years.

The European Thyroid Association 2022 guidelines on antithyroid drug management acknowledge that "ethnicity-specific data on ATD efficacy and adverse effects are insufficient to guide differential dosing recommendations" and call for pharmacogenomic research in underrepresented populations. Bartalena L, et al., Eur Thyroid J 2022.